Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
Autor(a) principal: | |
---|---|
Data de Publicação: | 2002 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
dARK ID: | ark:/48912/00130000005zr |
Texto Completo: | https://www.intmedpress.com/journals/avt/abstract.cfm?id=1223&pid=88 http://repositorio.unifesp.br/handle/11600/42610 |
Resumo: | Objectives: Indinavir is a widely prescribed protease inhibitor in the treatment of HIV infection. It has been associated with nephrolithiasis, crystalluria and tubulointerstitial nephritis. Nelfinavir is another protease inhibitor used successfully in AIDS treatment. The objective of this study was to evaluate the effect of both indinavir and nelfinavir individually, and in association with trimethoprim-sulfamethoxazole (TMP/SMX), on renal function in Wistar rats.Methods: Doses of indinavir (80 mg/kg body weight [BW] daily), nelfinavir (75 mg/kg BW daily) and TMP/SMX (100 mg TMP/kg BW daily) were given by gavage for 15 days. Seven groups were studied: control, vehicle, TMP/SMX, indinavir, indinavir+TMP/SMX, nelfinavir, and nelfinavir+TMP/SMX.Results: No changes were observed in body weight, urine volume and blood pressure. The vehicle group did not differ from the control group. TMP/SMX induced a small decrease in inulin clearance with no tubular alterations. Indinavir decreased inulin clearance (indinavir: 0.48 +/- 0.03 vs control: 0.93 +/- 0.08, P<0.001) and renal blood flow (indinavir: 6.2 +/- 0.2 vs control: 8.0 +/- 0.3, P<0.05). These effects were potentiated by TMP/SMX, which produced high vasoconstriction associated with alterations in tubular functions, characterised by increased fractional excretion of sodium (indinavir+TMP/SMX: 1.14 +/- 0.16 vs control: 0.39 +/- 0.07, P<0.01). Nelfinavir either alone or in combination with TMP/SMX did not change the renal function of the rats.Conclusion: These results suggest that indinavir nephrotoxicity in rats is potentiated by TMP/SMX and that nelfinavir alone or in combination with TMP/SMX is not nephrotoxic. |
id |
UFSP_b195ea1f681d51c8198bdadb45c2b6fb |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/42610 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicityObjectives: Indinavir is a widely prescribed protease inhibitor in the treatment of HIV infection. It has been associated with nephrolithiasis, crystalluria and tubulointerstitial nephritis. Nelfinavir is another protease inhibitor used successfully in AIDS treatment. The objective of this study was to evaluate the effect of both indinavir and nelfinavir individually, and in association with trimethoprim-sulfamethoxazole (TMP/SMX), on renal function in Wistar rats.Methods: Doses of indinavir (80 mg/kg body weight [BW] daily), nelfinavir (75 mg/kg BW daily) and TMP/SMX (100 mg TMP/kg BW daily) were given by gavage for 15 days. Seven groups were studied: control, vehicle, TMP/SMX, indinavir, indinavir+TMP/SMX, nelfinavir, and nelfinavir+TMP/SMX.Results: No changes were observed in body weight, urine volume and blood pressure. The vehicle group did not differ from the control group. TMP/SMX induced a small decrease in inulin clearance with no tubular alterations. Indinavir decreased inulin clearance (indinavir: 0.48 +/- 0.03 vs control: 0.93 +/- 0.08, P<0.001) and renal blood flow (indinavir: 6.2 +/- 0.2 vs control: 8.0 +/- 0.3, P<0.05). These effects were potentiated by TMP/SMX, which produced high vasoconstriction associated with alterations in tubular functions, characterised by increased fractional excretion of sodium (indinavir+TMP/SMX: 1.14 +/- 0.16 vs control: 0.39 +/- 0.07, P<0.01). Nelfinavir either alone or in combination with TMP/SMX did not change the renal function of the rats.Conclusion: These results suggest that indinavir nephrotoxicity in rats is potentiated by TMP/SMX and that nelfinavir alone or in combination with TMP/SMX is not nephrotoxic.USP, Lab Pesquisa Basica, Fac Med, Disciplina Nefrol, BR-09500900 Sao Paulo, BrazilUniv Fed Sao Paulo, Sao Paulo, BrazilUniv Fed Sao Paulo, Sao Paulo, BrazilWeb of ScienceInt Medical Press LtdUniversidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)Araujo, Magali de [UNIFESP]Seguro, Antonio Carlos2018-06-15T13:50:16Z2018-06-15T13:50:16Z2002-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion181-184https://www.intmedpress.com/journals/avt/abstract.cfm?id=1223&pid=88Antiviral Therapy. London: Int Medical Press Ltd, v. 7, n. 3, p. 181-184, 2002.1359-6535http://repositorio.unifesp.br/handle/11600/42610WOS:000179501500005ark:/48912/00130000005zrengAntiviral Therapyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-05-02T13:57:39Zoai:repositorio.unifesp.br/:11600/42610Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T19:48:02.767366Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity |
title |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity |
spellingShingle |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity Araujo, Magali de [UNIFESP] |
title_short |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity |
title_full |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity |
title_fullStr |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity |
title_full_unstemmed |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity |
title_sort |
Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity |
author |
Araujo, Magali de [UNIFESP] |
author_facet |
Araujo, Magali de [UNIFESP] Seguro, Antonio Carlos |
author_role |
author |
author2 |
Seguro, Antonio Carlos |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Universidade de São Paulo (USP) Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Araujo, Magali de [UNIFESP] Seguro, Antonio Carlos |
description |
Objectives: Indinavir is a widely prescribed protease inhibitor in the treatment of HIV infection. It has been associated with nephrolithiasis, crystalluria and tubulointerstitial nephritis. Nelfinavir is another protease inhibitor used successfully in AIDS treatment. The objective of this study was to evaluate the effect of both indinavir and nelfinavir individually, and in association with trimethoprim-sulfamethoxazole (TMP/SMX), on renal function in Wistar rats.Methods: Doses of indinavir (80 mg/kg body weight [BW] daily), nelfinavir (75 mg/kg BW daily) and TMP/SMX (100 mg TMP/kg BW daily) were given by gavage for 15 days. Seven groups were studied: control, vehicle, TMP/SMX, indinavir, indinavir+TMP/SMX, nelfinavir, and nelfinavir+TMP/SMX.Results: No changes were observed in body weight, urine volume and blood pressure. The vehicle group did not differ from the control group. TMP/SMX induced a small decrease in inulin clearance with no tubular alterations. Indinavir decreased inulin clearance (indinavir: 0.48 +/- 0.03 vs control: 0.93 +/- 0.08, P<0.001) and renal blood flow (indinavir: 6.2 +/- 0.2 vs control: 8.0 +/- 0.3, P<0.05). These effects were potentiated by TMP/SMX, which produced high vasoconstriction associated with alterations in tubular functions, characterised by increased fractional excretion of sodium (indinavir+TMP/SMX: 1.14 +/- 0.16 vs control: 0.39 +/- 0.07, P<0.01). Nelfinavir either alone or in combination with TMP/SMX did not change the renal function of the rats.Conclusion: These results suggest that indinavir nephrotoxicity in rats is potentiated by TMP/SMX and that nelfinavir alone or in combination with TMP/SMX is not nephrotoxic. |
publishDate |
2002 |
dc.date.none.fl_str_mv |
2002-09-01 2018-06-15T13:50:16Z 2018-06-15T13:50:16Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.intmedpress.com/journals/avt/abstract.cfm?id=1223&pid=88 Antiviral Therapy. London: Int Medical Press Ltd, v. 7, n. 3, p. 181-184, 2002. 1359-6535 http://repositorio.unifesp.br/handle/11600/42610 WOS:000179501500005 |
dc.identifier.dark.fl_str_mv |
ark:/48912/00130000005zr |
url |
https://www.intmedpress.com/journals/avt/abstract.cfm?id=1223&pid=88 http://repositorio.unifesp.br/handle/11600/42610 |
identifier_str_mv |
Antiviral Therapy. London: Int Medical Press Ltd, v. 7, n. 3, p. 181-184, 2002. 1359-6535 WOS:000179501500005 ark:/48912/00130000005zr |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Antiviral Therapy |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
181-184 |
dc.publisher.none.fl_str_mv |
Int Medical Press Ltd |
publisher.none.fl_str_mv |
Int Medical Press Ltd |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1818602373614927872 |